Immune Oncology

Clinical Neuroscience

MARCH 30, 2024

[Thrombolysis treatment and multi- disciplinary management of central retinal artery occlusion in comparison with traditional ophthalmological treatment options ]

VAJDA Szilvia, GUNDA Bence, KNÉZY Krisztina, BARSI Péter, VARGA Csaba, MAUROVICH-HORVAT Pál, BERECZKI Dániel, NAGY Zoltán Zsolt

[The management of central retinal artery occlusion (CRAO) has long been conservative therapy with limited efficacy carried out in ophthalmology departments together with etiolo­gi­cal investigations lacking a standardised protocol. However, CRAO is analogous to ischemic central nervous system stroke and is associated with increased stroke risk, thus, systemic thrombolysis treatment and multidisciplinary management can be beneficial. Since May 2022, at Semmelweis University CRAO patients diagnosed within 4.5 hours are given intravenous thrombolysis therapy and undergo etiologic workup based on current stroke protocols. Here we report our experience with the multidisciplinary, protocol-based management of CRAO in comparison with former non-protocol based ophthalmological conservative treatment.

We reviewed CRAO patients’ data treated conservatively and with paracentesis within 6 hours at the Department of Ophthalmology between 2013 and 2022 including changes in visual acuity, neurolo­gical and cardiovascular findings compared to those in the thrombolysis project. 

Of the 78 patients receiving non-protocol care, visual improvement was seen in 37% with natural course, 47% with conservative treatment and 47% with paracentesis. Four patients had significant carotid stenosis (2 underwent endarterectomy), 1 carotid dissection, 6 cardioembolism and 1 giant cell arteritis. Of the 4 patients within 4,5 hours, 3 gave their consent to the clinical trial and were treated with thrombolysis and underwent a full etiological assessment. 
2 pa­tients had improved visual acuity, 2 pa­tients had significant carotid stenosis and underwent endarterectomy, 1 patient was started on anticoagulation for newly diagnosed atrial fibrillation.

CRAO patients presenting within 4,5 hours are rare and more patients are needed in our study to establish the efficacy of thrombolysis. However uniform protocollized evaluation helps identifying embolic sources thus, avoiding further and potentially more serious thromboembolic events.]

HUN 2024;77(3-4)

Clinical Neuroscience

MARCH 30, 2024

Perineural 5% dextrose versus corticosteroid injection in non-surgical carpal tunnel syndrom treatment

OZGE OCEK, DERYA GUNER

We aimed to investigate the difference of clinical and electrophysiological improvement between perineural corticosteroid injection therapy and perineural 5% dextrose injection therapy in carpal tunnel syndrome. Total of 92 wrists that were diagnosed as mild-to-moderate idiopathic CTS and completed their follow-up were included in our study. The severity of pain, symptom severity and functional status were assessed by visual analog scale.

ENG 2024;77(3-4)

Hypertension and nephrology

FEBRUARY 28, 2024

[Important effects of renin-angiotensin system and angiotensin receptor blockers. Focus on valsartan]

FARSANG Csaba

[Blockade of AT1-receptors causes arteriolar vasodilation leading to the decrease the total peripheral resistance (TPR), the aldosterone secretion, and the sodium reabsorption in renal tubuli with reduction of the intraglomerular pressure.]

HUN 2024;28(1)

Clinical Neuroscience

JANUARY 30, 2024

Glioblastoma epigenomics discloses a complex biology and potential therapeutic targets

KRABÓTH Zoltán , TOMPA Márton , URBÁN Péter , GÁLIK Bence , KAJTÁR Béla , GYENESEI Attila , KÁLMÁN Bernadette

Glioblastoma (GBM), a highly aggressive form of brain tumors, has been extensively studied using OMICS methods, and the most characteristic molecular determinants have been incorporated into the histopathological diagnosis. Research data, nevertheless, only partially have been adopted in clinical practice. Here we aimed to present results of our epigeno­ mic GBM profiling to better understand early and late determinants of these tumors, and to share main elements of our findings with practicing professionals.

ENG 2024;77(1-2)